Infinity Pharmaceuticals Inc. (NASDAQ:INFI) major shareholder Value Fund L. P. Biotechnology bought 1,510,000 shares of the company’s stock in a transaction on Tuesday, April 10th. The shares were acquired at an average price of $1.97 per share, for a total transaction of $2,974,700.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ INFI opened at $2.20 on Friday. Infinity Pharmaceuticals Inc. has a 12-month low of $0.93 and a 12-month high of $3.75. The company has a market cap of $113.80, a price-to-earnings ratio of -2.65 and a beta of 2.49.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.11. sell-side analysts forecast that Infinity Pharmaceuticals Inc. will post -0.74 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC acquired a new stake in shares of Infinity Pharmaceuticals in the 4th quarter worth approximately $312,000. BVF Inc. IL grew its holdings in shares of Infinity Pharmaceuticals by 24.2% in the 4th quarter. BVF Inc. IL now owns 9,766,508 shares of the biotechnology company’s stock worth $19,826,000 after acquiring an additional 1,900,400 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Infinity Pharmaceuticals in the 3rd quarter worth approximately $135,000. Alambic Investment Management L.P. acquired a new stake in shares of Infinity Pharmaceuticals in the 4th quarter worth approximately $158,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Infinity Pharmaceuticals by 654.7% in the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 91,206 shares during the period. Institutional investors and hedge funds own 49.47% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Major Shareholder Value Fund L. P. Biotechnology Acquires 1,510,000 Shares” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/04/20/value-fund-l-p-biotechnology-acquires-1510000-shares-of-infinity-pharmaceuticals-inc-infi-stock.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.